Michael Frank Mørup1, Steven M Kymes2, Daniel Oudin Åström1. 1. Health Economics & Epidemiology Statistics, Department of Data Science, H Lundbeck A/S, Valby, Denmark. 2. H Lundbeck Deerfield, Deerfield, IL, United States of America.
Abstract
INTRODUCTION: Schizophrenia is a condition that places a significant burden on individuals with the condition, their family, and society. A large proportion of those treated for schizophrenia do not experience treatment response and are referred to as having "treatment-resistant schizophrenia" (TRS). Expert opinion has long held that the prevalence of TRS among individuals with schizophrenia is 30%, but the basis of this estimate is unclear. This article presents a model developed for estimating the prevalence of TRS in the United States 2014. METHODS: An incidence-prevalence-mortality model was developed to estimate the prevalence of TRS in the United States. The model was populated with data from public health agencies and published literature. Prevalence in 2014 was modelled using a Markov cohort simulation for each birth cohort between 1930 to 2014. RESULTS: Using different scenarios for baseline incidence, relative risks of mortality, it was estimated that approximately 22% of individuals with schizophrenia would be considered treatment-resistant in 2014. DISCUSSION: The results suggests that prevalence of TRS may be somewhat lower than the 30% often reported, however this is highly dependent on the definition of treatment resistance. Methods such as this may help answer epidemiological and health policy questions as well as test the influence of key underlying assumptions.
INTRODUCTION:Schizophrenia is a condition that places a significant burden on individuals with the condition, their family, and society. A large proportion of those treated for schizophrenia do not experience treatment response and are referred to as having "treatment-resistant schizophrenia" (TRS). Expert opinion has long held that the prevalence of TRS among individuals with schizophrenia is 30%, but the basis of this estimate is unclear. This article presents a model developed for estimating the prevalence of TRS in the United States 2014. METHODS: An incidence-prevalence-mortality model was developed to estimate the prevalence of TRS in the United States. The model was populated with data from public health agencies and published literature. Prevalence in 2014 was modelled using a Markov cohort simulation for each birth cohort between 1930 to 2014. RESULTS: Using different scenarios for baseline incidence, relative risks of mortality, it was estimated that approximately 22% of individuals with schizophrenia would be considered treatment-resistant in 2014. DISCUSSION: The results suggests that prevalence of TRS may be somewhat lower than the 30% often reported, however this is highly dependent on the definition of treatment resistance. Methods such as this may help answer epidemiological and health policy questions as well as test the influence of key underlying assumptions.
Authors: Antonio F Pardiñas; Sophie E Smart; Isabella R Willcocks; Peter A Holmans; Charlotte A Dennison; Amy J Lynham; Sophie E Legge; Bernhard T Baune; Tim B Bigdeli; Murray J Cairns; Aiden Corvin; Ayman H Fanous; Josef Frank; Brian Kelly; Andrew McQuillin; Ingrid Melle; Preben B Mortensen; Bryan J Mowry; Carlos N Pato; Sathish Periyasamy; Marcella Rietschel; Dan Rujescu; Carmen Simonsen; David St Clair; Paul Tooney; Jing Qin Wu; Ole A Andreassen; Kaarina Kowalec; Patrick F Sullivan; Robin M Murray; Michael J Owen; James H MacCabe; Michael C O'Donovan; James T R Walters; Olesya Ajnakina; Luis Alameda; Thomas R E Barnes; Domenico Berardi; Elena Bonora; Sara Camporesi; Martine Cleusix; Philippe Conus; Benedicto Crespo-Facorro; Giuseppe D'Andrea; Arsime Demjaha; Kim Q Do; Gillian A Doody; Chin B Eap; Aziz Ferchiou; Marta Di Forti; Lorenzo Guidi; Lina Homman; Raoul Jenni; Eileen M Joyce; Laura Kassoumeri; Inès Khadimallah; Ornella Lastrina; Roberto Muratori; Handan Noyan; Francis A O'Neill; Baptiste Pignon; Romeo Restellini; Jean-Romain Richard; Franck Schürhoff; Filip Španiel; Andrei Szöke; Ilaria Tarricone; Andrea Tortelli; Alp Üçok; Javier Vázquez-Bourgon Journal: JAMA Psychiatry Date: 2022-03-01 Impact factor: 25.911
Authors: Giouliana Kadra-Scalzo; Daniela Fonseca de Freitas; Deborah Agbedjro; Emma Francis; Isobel Ridler; Megan Pritchard; Hitesh Shetty; Aviv Segev; Cecilia Casetta; Sophie E Smart; Anna Morris; Johnny Downs; Søren Rahn Christensen; Nikolaj Bak; Bruce J Kinon; Daniel Stahl; Richard D Hayes; James H MacCabe Journal: PLoS One Date: 2022-09-19 Impact factor: 3.752
Authors: Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Mustafa Al-Zamil; Andrey P Otmakhov; Nikolay G Neznanov; German A Shipulin; Marina M Petrova; Natalia P Garganeeva; Regina F Nasyrova Journal: Int J Mol Sci Date: 2022-09-26 Impact factor: 6.208